Morrow, Sara
Department of Medical Oncology and
3 papers on CoChat
Most cited papers
- Verified
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., et al. (2018) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 290
- Verified
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood
Protein Degradation and InhibitorsChronic Lymphocytic Leukemia Research
Cited by 169
- Verified
Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
Sceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M., Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., et al. (2019) · Cancer Discovery
Cancer Immunotherapy and Biomarkersinterferon and immune responses
Cited by 156
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free